Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.90, $0.04 better than the analyst estimate of $2.86. Revenue for the quarter came in at $25.31 billion versus the consensus estimate of $25.02 billion.

GUIDANCE:

Johnson & Johnson sees FY2026 EPS of $11.50-$11.65, versus the consensus of $11.58. Johnson & Johnson sees FY2026 revenue of $100.8-101.4 billion, versus the consensus of $101.06 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Anthropic delays planned IPO from October to November - WSJ
• Teva shares Phase 3 data on once-monthly schizophrenia injection